Nordic Capital and Avista to sell Acino to ADQ

Financial terms of the transaction were not disclosed. The deal is subject to customary closing conditions, including regulatory approvals.

Avista and Nordic Capital acquired Acino in a 2013 take-private for an enterprise value of CHF 544m (EUR 444m). Originally a Nordic Capital Fund VII portfolio company, the GP transferred Acino to a continuation vehicle, Nordic Capital CV1, in 2018. The transfer of nine Nordic Capital portfolio companies was worth €2.5bn, according to Unquote Data. The deal saw Goldman Sachs and Coller Capital invest in the continuation vehicle.

In a statement, the vendors claimed they transformed the business to become an emerging-markets-focused pharmaceuticals platform with significant market presence in the Middle East, Ukraine, Russia and South Africa. Acino has completed a number of bolt-ons since 2013, including PharmaStart (Ukraine), Litha Healthcare (South Africa), and the acquisition of a portfolio of over-the-counter and prescription pharmaceutical assets from Takeda Pharmaceuticals.

Company
Founded in 1961, Acino is a pharmaceutical company headquartered in Zurich. The company develops, manufactures and internationally markets pharmaceuticals in novel drug delivery forms.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• DACH
• Healthcare
• Nordic Capital